Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperilate SCHEMBL26493 | 0.94 | ALDH1A1 (0.78) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| Piperilate SCHEMBL1650954 | 0.92 | ALDH1A1 (0.76) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL25142218 | 0.80 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL3361921 | 0.78 | HTT (0.54) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL3365837 | 0.77 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL5158545 | 0.75 | MEN1 (0.68) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL9588270 | 0.74 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL9589541 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL5161453 | 0.72 | MEN1 (0.64) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| Benactyzine SCHEMBL7799126 | 0.72 | MEN1 (0.92) | KMT2AMEN1KDM4EPOLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647648-B1 | Solid dosage form containing a low viscosity HYDROXYALKYL CELLULOSE | NIPPON SODA CO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150342895-A1 | HYDROXYALKYL CELLULOSE | NIPPON SODA CO (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-1953164-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR FUNCTIONAL BOWEL DISORDER | TORAY INDUSTRIES (JP) | 2014-05-14 | — | — | EP | disclosed |
| EP-2647648-A1 | HYDROXYALKYL CELLULOSE | Nippon Soda Co., Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130243870-A1 | HYDROXYALKYL CELLULOSE | NIPPON SODA CO., LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8058286-B2 | Method for therapy of diarrhea-predominant irritable bowel disorders | TORAY INDUSTRIES, INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20090111843-A1 | Therapeutic or Prophylactic Agent for Functional Bowel Disorder | TORAY INDUSTRIES, INC. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1953164-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR FUNCTIONAL BOWEL DISORDER | TORAY INDUSTRIES, INC. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| US-20070166362-A1 | Transdermal and transmucosal preparations | KABUSHIKI KAISHA SANGI (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1797900-A1 | PREPARATION FOR PERCUTANEOUS/PERMUCOSAL ABSORPTION | KABUSHIKI KAISHA SANGI (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111843-A1 | Therapeutic or Prophylactic Agent for Functional Bowel Disorder | SLC10A2, ALPI, SI | ALDH1A1 2421/4885KMT2A 3808/4885MEN1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.